Europe Urinary Tract Infections Market

Europe Urinary Tract Infections Market Size (2023 to 2028)

The Urinary Tract Infections Market size in Europe is forecasted to be worth USD 2.75 billion by 2028 from USD 2.47 billion in 2023. This market is estimated to be growing at a CAGR of 2.13% during the forecast period.

An increase in the incidence of diabetes and kidney stones is majorly driving the European Urinary tract infections market. Also, the proliferation of hospitals acquired urinary tract infections, technological advancement is changing, and improving the scenario for Urinalysis testing propels the market growth. Growing geriatric population is more prone to various chronic diseases. Diabetes and urological health issues are closely connected. Diabetes results in UTIs and bladder issues, and It can often make urologic conditions even worse because it can impact blood flow, nerves, and sensory functions in the body; therefore, the increasing prevalence of diabetes and kidney stones, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs, thus, driving the European urinary tract infection therapeutics market. In addition, the Adoption of advanced technology is providing lucrative opportunities for the market players, which is expected to expand the market growth. 

On the other hand, the market is growing at a significant pace owing to the introduction of highly automated instruments with the help of technology for better diagnosis development. In addition, increasing investment and funding by the government and private organizations to introduce a more efficient combination of drugs is more likely to expand the market growth in the region. 

According to research published in Advances in Urology 2018, kidney stone disease is a growing urological health problem that affects around 15% of the world's population. It affects people of all ages, although it affects males more than women between 20 and 49. Furthermore, around 7% of women and 13% will acquire a kidney stone throughout their lifetime.

However, the high cost associated with the research and studies impedes market growth, indirectly affecting the launch of new products in the market. Additionally, the lack of awareness about the prevalence of UTIs in developing and underdeveloped countries is also restraining the market's growth.

This research report on the Europe Urinary Tract Infections Market has been segmented and sub-segmented into the following categories:

By Type of Medication:

• Penicillin & Combinations 
  • Amoxicillin
  • Amoxicillin-Clavulanate Potassium combination
• Quinolones             
  • Ciprofloxacin
  • Levofloxacin
  • Norfloxacin
  • Nalidixic Acid
• Aminoglycoside-Antibodies             
  • Gentamicin
  • Amikacin
• Cephalosporin       
  • Ceftriaxone
  • Cefixime
  • Cefuroxime
  • Cephalexin
• Sulphonamides     
  • Sulfamethoxazole
  • Trimethoprim combination
• Azoles & Amphotericin B  
• Tetracycline            
  • Doxycycline
  • Nitrofurans
• Nitrofurans 

By Type of Indication:

• Uncomplicated UTI
• Complicated UTI   
• Recurring Complicated UTI               
• Neurogenic Bladder Infection 

By Country:

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Rest of Europe

Regionally, the European market had accounted for the second-most significant share in the global market in 2022. Moreover, the market is anticipated to witness a significant share over the forecast period. The European regional market growth is projected to be fuelled by the rapidly increasing geriatric population, increasing consumer awareness, and favorable government policies. In addition, the proliferation of kidney and diabetes are majorly propelling the market growth in the region. The major growth contributors in the region are Germany, UK, France, Spain, and Italy.

Over the forecast period, the UK dominated the urinary tract infections market and anticipated to share a significant share of the European regional market growth. Initiatives taken by the government for creating medical tourism in the country for creating healthcare awareness among the people are positively influencing the market growth.

On the other hand, Germany is projected to hold a significant share in the urinary tract market owing to the advancing healthcare infrastructure, increasing investment by the government, and non-government organizations are augmenting the market growth. In addition, the incidence of urinary infections in women is higher than that in men. Therefore, increasing focus on women's healthcare in the region is likely to increase the market growth.

Similarly, the countries such as France, Spain, and Italy are anticipated to contribute to the European regional market growth.

KEY MARKET PLAYERS:

Companies playing a prominent role in the European Urinary Tract Infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.